Search | Clinical Trials Finder

Conditions: Fluid Balance
Interventions: Placebo beverage, kiwi-strawberry flavor, Electrolyte solution without glycerol beverage 1, Electrolyte solution without glycerol beverage 2, Electrolyte solution without glycerol beverage 3, Electrolyte solution with glycerol beverage 1, Electrolyte solution with glycerol beverage 2, Electrolyte solution with glycerol beverage 3, Base with glycerol, no electrolytes beverage 1, Base with glycerol, no electrolytes beverage 2, Base with glycerol, no electrolytes beverage 3; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Bradenton, Florida • St. Petersburg, Florida • Valhalla, New York

Conditions: Autoimmune Epilepsy
Interventions: Intravenous Immunoglobulin, Placebos, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sickle Cell Anemia
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions: Rejuveinix (RJX) Active Comparator, Placebo Comparator; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Houston, Texas • New Braunfels, Texas

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Sodium Nitroprusside, 5% Dextrose solution; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Leptin Resistance
Interventions: Saline, Intralipid, Water, oral fat, Heparin; Drug · Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions: Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss; Drug · Other
Lead sponsor: Chattanooga-Hamilton County Hospital Authority; Other
Eligibility: 1 Year to 21 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Bronchopulmonary Dysplasia
Interventions: Furosemide (plus potassium chloride), Placebo (plus placebo electrolyte solution); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Weeks to 10 Weeks
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST); Drug · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colonoscopy
Interventions: lubiprostone (Amitiza), Placebo; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Detroit, Michigan • Novi, Michigan • West Bloomfield, Michigan

Conditions: Dehydration, Dehydration Related to Exercise
Interventions: carbohydrate electrolyte drink, no-sugar electrolyte drink, Caffeinated Carbohydrate and electrolyte drink, Water (Placebo); Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Rett Syndrome
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: Glutamine, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 1,433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 15
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more

Conditions: Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions: Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Colonoscopy
Interventions: Simethicone Solution, Water; Drug
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Reno, Nevada

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions: Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O); Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Failure, Acute, Renal Replacement Therapy
Interventions: Sodium bicarbonate, Normal saline, Bicarbonate, Placebo; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions: B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 24 Months to 59 Months
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more

Conditions: Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women, Post-menopausal Women, Hydration
Interventions: placebo beverage, electrolyte beverage; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Bradenton, Florida • Valhalla, New York

Conditions: Fluid Balance
Interventions: Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2), 0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only), 0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only), 1% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2), 6% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2), 6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only), 2% carbohydrate electrolyte solution without glycerol beverage (Part 2 only); Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Valhalla, New York

Search by objective public record fields.

Effects of Beverage Volume, Glycerol Concentration, and Sodium Concentration on Fluid Balance in Healthy Euhydrated Men and Women at Rest

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Tolerability and Efficacy of RJX in Patients With COVID-19

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Sodium Nitroprusside in Early Course Schizophrenia

Effect of Increased Free Fatty Acids on Leptin Function

Investigation of Sleep in the Intensive Care Unit

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Pragmatic Research on Diuretic Management in Early BPD Pilot

Effect of Insulin Lowering on Lipogenesis

Treatment of Orthostatic Intolerance

Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation

The Impact of a Caffeinated Sports Drink on Performance

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

A Low ChloridE hyperTonic Solution for Brain Edema

Evaluation of Oral Simethicone With Low Volume Polyethylene Glycol Bowel Preparation During Colonoscopy

Glycemic Effect of Diazoxide in NAFLD

Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

Hydration & Female Life Stages

Effect of Adding Glycerol to Electrolyte Beverages on Fluid Balance in Healthy Euhydrated Men and Women at Rest